Search results
Jun 4, 2024 · • 2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%* • 2024 Second-Quarter Earnings per share (EPS) of $1.93 decreasing by 5.9% due to one-time special charges and adjusted EPS of $2.82 increasing by 10.2%* • Significant new product ...
Apr 29, 2024 · Every year, roughly 2 million people in the U.S. are newly diagnosed with cancer. But a number of scientific breakthroughs—including ones made at Johnson & Johnson—have dramatically changed what kind of prognosis many of these patients will have.
In the 1930s the company commissioned a series of colorful panels to pay homage to men and women who worked at Johnson & Johnson. For Employee Appreciation Day, we tell the story behind the art. Read more
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today we are committed to using our reach and size for good.
This site is published by Johnson & Johnson Medical Limited, which is solely responsible for its content. It is intended for use by Eye Care Professionals of the United Kingdom and the Republic of Ireland.
Sep 14, 2023 · Johnson & Johnson Innovative Medicine is leading where medicine is going. Innovative Medicine Learn about pharmaceutical products for treatments including immunology, cardiovascular disease, pulmonary hypertension, infectious diseases, and oncology.
Nov 12, 2021 · New Consumer Health Company would be a Global Leader with Iconic Brands and Products that Touch Over One Billion Lives Every Day Johnson & Johnson would Remain a Global Leader in Healthcare, Focused on Major Unmet Medical Needs and Materially Advancing Standard of Care through Biopharmaceutical and Medical Device Innovation and Technology Separation Designed to Enhance Operational Performance ...
